Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Investor Relations > Press Releases

Press Releases

All Releases
View Summary Spectrum Pharmaceuticals Announces First Quarter 2017 Financial Results Teleconference and Webcast
Apr 25, 2017
PDF 14.4 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Preclinical Data of ROLONTIS™ (eflapegrastim) at the American Association for Cancer Research (AACR) Annual Meeting
Apr 4, 2017
PDF 16.7 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Three Abstracts on ROLONTIS™ (eflapegrastim) and BELEODAQ® (belinostat) for injection at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C., April 1-5, 2017
Mar 31, 2017
PDF 15.1 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
Mar 30, 2017
PDF 17.2 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results and Pipeline Update
Mar 8, 2017
PDF 43.1 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results Teleconference and Webcast
Mar 1, 2017
PDF 14.4 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the 2017 RBC Capital Markets Global Healthcare Conference on February 23rd
Feb 16, 2017
PDF 13.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer
Dec 8, 2016
PDF 61.3 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Survival Advantage in a Case Match Control Analysis of the PROPEL Study with FOLOTYN® (pralatrexate injection) at the 58th Annual Meeting of the American Society of Hematology (ASH)
Dec 6, 2016
PDF 18.6 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Five Abstracts on ROLONTIS™ (eflapegrastim) and Poziotinib at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016
Dec 5, 2016
PDF 16.6 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Four Abstracts at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, December 3-6, 2016
Dec 2, 2016
PDF 16.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference on Lung Cancer in Vienna, Austria, December 4-7, 2016
Nov 17, 2016
PDF 15.7 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Provides Third Quarter Financial Update
Nov 14, 2016
PDF 34.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Provides Third Quarter Financial and Pipeline Update
Nov 3, 2016
PDF 19.1 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Third Quarter 2016 Financial Results Teleconference and Webcast
Oct 27, 2016
PDF 14.4 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Appointment of Luigi Lenaz, M.D., as Lead Director
Oct 18, 2016
PDF 14.0 KB Add to Briefcase
View Summary FDA Advisory Committee Votes that Qapzola™ (apaziquone) Has Not Shown Substantial Evidence of a Treatment Effect Over Placebo
Sep 14, 2016
PDF 13.3 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Pipeline Update
Aug 9, 2016
PDF 42.8 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Second Quarter 2016 Financial Results Teleconference and Webcast
Aug 2, 2016
PDF 14.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Settles FOLOTYN® (pralatrexate injection) ANDA Patent Litigation
Jul 13, 2016
PDF 13.5 KB Add to Briefcase
Showing 21-40 of 721 Page: 1 2 3 4 5 6 ... 37  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

NASDAQ: SPPI

Price:
19.82
Change:
0.00
Day High:
N/A
Day Low:
N/A
Volume:
N/A
4:00 PM ET on Nov 21, 2017
Delayed at least 20 minutes.
Provided by eSignal.

Shareholder Tools

Print Email

Search IR